These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37033782)

  • 1. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.
    Talamonti M; Russo F; Malara G; Hansel K; Papini M; Cattaneo A; Parodi A; Chiricozzi A; Malagoli P; Bardazzi F; Brazzelli V; Dapavo P; Gisondi P; Zane C; Potenza C; Cantoresi F; Fargnoli MC; Trevisini S; Brianti P; Pescitelli L; Gigante G; Bartezaghi M; Caputo L; Aloisi E; Costanzo A;
    Clin Cosmet Investig Dermatol; 2023; 16():847-852. PubMed ID: 37033782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study.
    Stingeni L; Malara G; Conti A; Di Costanzo L; Carrera CG; Burlando M; Malagoli P; Musumeci ML; Bardazzi F; Brazzelli V; Amerio P; De Simone C; Trevisini S; Balato A; Megna M; Loconsole F; De Felice C; Bartezaghi M; Rausa A; Aloisi E; Orsenigo R; Costanzo A;
    Clin Cosmet Investig Dermatol; 2023; 16():27-38. PubMed ID: 36636635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
    Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A; Papavassilis C; Bhosekar V; Reinhardt M
    Drugs Aging; 2018 Feb; 35(2):135-144. PubMed ID: 29404966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.
    Talamonti M; Malara G; Natalini Y; Bardazzi F; Conti A; Chiricozzi A; Mugheddu C; Gisondi P; Piaserico S; Pagnanelli G; Amerio P; Potenza C; Cantoresi F; Fargnoli MC; Balato A; Loconsole F; Offidani A; Bonifati C; Prignano F; Bartezaghi M; Rausa A; Aloisi E; Orsenigo R; Costanzo A;
    Acta Derm Venereol; 2021 Mar; 101(3):adv00422. PubMed ID: 33269404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
    Reich K; Körber A; Mrowietz U; Sticherling M; Sieder C; Früh J; Bachhuber T
    Br J Dermatol; 2021 May; 184(5):849-856. PubMed ID: 32652528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
    Warren RB; Barker JNWB; Finlay AY; Burden AD; Kirby B; Armendariz Y; Williams R; Hatchard C; Khare S; Griffiths CEM
    Br J Dermatol; 2020 Jul; 183(1):60-70. PubMed ID: 31628677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
    Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
    Bagel J; Nia J; Hashim PW; Patekar M; de Vera A; Hugot S; Sheng K; Xia S; Gilloteau I; Muscianisi E; Blauvelt A; Lebwohl M
    Dermatol Ther (Heidelb); 2018 Dec; 8(4):571-579. PubMed ID: 30334147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.
    Bhat RM; Leelavathy B; Aradhya SS; Gopal MG; Pratap DV; Mubashir M; Srinivas P; Pande SY; Thavkar AS
    Indian Dermatol Online J; 2017; 8(1):16-24. PubMed ID: 28217466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
    Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
    Magnolo N; Kingo K; Laquer V; Browning J; Reich A; Szepietowski JC; Keefe D; Papanastasiou P; Bao W; Forrer P; Patekar M
    Paediatr Drugs; 2022 Jul; 24(4):377-387. PubMed ID: 35698000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients with Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp.
    Kyrmanidou E; Kemanetzi C; Stavros C; Trakatelli MG; Patsatsi A; Madia X; Ignatiadi D; Kalloniati E; Apalla Z; Lazaridou E
    Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.